High specificity for the DNA repair enzyme PARP1 with therapeutic effect. Promising new targeted antitumor drug, which is already in clinical trials. High tumor-background fluorescent ratio. Toxicity profile is known and similar to Olaparib. This evidence concerns the gene PARP1 and neoplasm.